A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

Part of paid clinical trials in Anaheim, California.

Sponsor
AbbVie
Study ID
NCT07514260
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • ABBV-295 — DRUG
    Subcutaneous Injections
  • Placebo for ABBV-295 — DRUG
    Subcutaneous Injections

Study Details

The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.

Key Dates

Start date
Mar 31, 2026
Status verified
Mar 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: ABBV-295 Part 1
    Participants will receive subcutaneous doses of ABBV-295 for 12 weeks.
  • Experimental: Placebo for ABBV-295 Part 1
    Participants will receive subcutaneous doses of placebo for 12 weeks.
  • Experimental: ABBV-295 Part 2
    Participants will receive subcutaneous doses of ABBV-295 for 12 weeks.
  • Experimental: Placebo for ABBV-295 Part 2
    Participants will receive subcutaneous doses of placebo for 12 weeks.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to approximately 138 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
CenExel ACT- Anaheim Clinical Trials /ID# 280879AnaheimCalifornia92801-

Find similar trials in Anaheim, CA

By research site
CenExel ACT- Anaheim Clinical Trials· Anaheim, CA

Related Studies